ReviewAmerican journal of translational research2021

Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations.

Taylor Ryan McFarland et al.PubMed ↗Full text ↗

No numbers read from the abstract.